Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07311850 · ClinicalTrials.gov registry record · Phase 3

Efficacy and Safety of MET097 Once-Weekly in People With Overweight or Obesity

A Phase 3 study of Obesity and Overweight, sponsored by Metsera, a wholly owned subsidiary of Pfizer.

Recruiting
Registry status
Phase 3
Development phase
3,500
Enrollment target
5
Study locations

NCT07311850 is a Phase 3 study of Obesity and Overweight that is actively recruiting participants, run by Metsera, a wholly owned subsidiary of Pfizer. The registered enrollment target is 3,500 participants, above the 336-participant average among 27 other Obesity and Overweight trials with a reported enrollment target (942% higher). The trial reports 5 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07311850, a Phase 3 study of Obesity and Overweight, is actively recruiting participants, sponsored by Metsera, a wholly owned subsidiary of Pfizer.

RECRUITING
Registry status
Phase 3
Development phase
3,500 participants
Enrollment target
5
Study locations

Study Summary

This study investigates the efficacy and safety of once weekly injectable MET097 in adult participants with obesity or overweight with weight-related comorbidities excluding T2D. This trial will last for a duration of 84 weeks. The primary endpoint will be assessed after 64 weeks of treatment with the secondary at 84 weeks.

Conditions Studied

Obesity and Overweight

Interventions

  • DRUG Placebo
  • DRUG MET097

Study Locations (5)

California

  • Research Site 97301-001007 - Riverside
  • Research Site 97301-001070 - Torrance

Colorado

  • Research Site 97301-001077 - Englewood

Florida

  • Research Site 97302-001001 - Hollywood

North Carolina

  • Research Site 97301-001309 - Cary

Trial Details

FieldValue
Enrollment Target 3,500 participants
Start Date 2025-12-29
Est. Completion 2028-05
Phase Phase 3

Sponsor

Metsera, a wholly owned subsidiary of Pfizer

7 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07311850

The ClinicalTrials.gov registry entry for NCT07311850 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 3,500 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 336-participant average among 27 other Obesity and Overweight trials with a reported enrollment target (942% higher). The listed sponsor is Metsera, a wholly owned subsidiary of Pfizer, which has 7 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Obesity and Overweight appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT07311850 reports 5 study locations spanning 4 distinct geographic areas - top geographies include California, Colorado, Florida.

Frequently Asked Questions

What is clinical trial NCT07311850 about?

NCT07311850 is a clinical study titled "Efficacy and Safety of MET097 Once-Weekly in People With Overweight or Obesity". This study investigates the efficacy and safety of once weekly injectable MET097 in adult participants with obesity or overweight with weight-related comorbidities excluding T2D. This trial will last for a duration of 84 weeks. The primary endpoint will be assessed after 64 weeks of treatment with t...

What is the current status of trial NCT07311850?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 3,500 participants. The study started on 2025-12-29. Estimated completion is 2028-05.

What conditions does trial NCT07311850 study?

This clinical trial studies the following conditions: Obesity and Overweight.

What interventions are being tested in trial NCT07311850?

The interventions under investigation include: Placebo (DRUG), MET097 (DRUG).

Who is sponsoring clinical trial NCT07311850?

This trial is sponsored by Metsera, a wholly owned subsidiary of Pfizer, which has 7 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07311850 being conducted?

This trial has 5 study locations across California, Colorado, Florida, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Obesity and Overweight

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Obesity and Overweight

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.